Skip to main content

PCAS: 2020 annual results

Written by Customer Service on . Posted in Public Companies.

Ecully, February 25, 20212020 ANNUAL RESULTS PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its 2020 results.  ResultsThe PCAS Group has generated consolidated net sales of €194.1 million in fiscal year 2020, a decrease of 3.4% (-2.7% at constant exchange rates) compared to fiscal year 2019.The EBITDA amounted to €10.7 million, compared to €16.3 million in 2019 (i.e. a margin of 5.5% versus 8.1% in 2019) and was primarily impacted negatively by the delay in commissioning the new production unit at the Villeneuve-la-Garenne site, the significant drop in demand for Lubricants linked to the coronavirus crisis as well as, to a lesser extent, the resources implemented to improve the industrial performance of several sites in the Pharmaceutical Synthesis activity. Consequently, the current operating income decreased to €-10.8 million, compared to €-3.5 million in 2019.As a reminder, other operating income and expenses included the costs associated with the reorganization of the Longjumeau site for €3.8 million in 2019.The financial result showed a loss of €1.6 million in 2020, compared to a loss of €2.1 million in 2019.The PCAS Group’s net result was a loss of €14.9 million in 2020, compared to a loss of €13.7 million in 2019.The Group’s net debt (including Net Current Account credit balance with Seqens) totaled €133.4 million vs. €97.7 million at December 31, 2019. Outlook for the current yearAs mentioned in our previous press releases since end-March 2020, the global health crisis relating to the coronavirus is changing by the day, and there is still a gray area surrounding its duration, its extent and its effects on companies’ production lines and consumption in general.The potential impacts in the medium term remain difficult to anticipate. This crisis calls for cautious measures. Due to the exceptional circumstances, the Group has suspended its financial targets and its strategic business objectives until the situation becomes clearer. DividendIn view of the Group’s financial performance in 2020, the Board of Directors will ask the next Annual General Meeting to approve no dividend payment on 2020 results. NEXT FINANCIAL DISCLOSURE:
2020 Shareholder’s Meeting, May 12, 2021, 10 a.m.ABOUT PCASPCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 10% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €194.1 million in 2020 and employs close to 1 100 people in six countries.To find out more about PCAS: www.pcas.com  AttachmentPCAS – Annual Results 2020_en-US

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.